Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Anti-CD3 MAb (OKT3) in Metabolic Syndrome/NASH
NCT01205087Phase 2Completed
- Sponsor
- Hadassah Medical Organization
- Start
- Sep 2010
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of muromonab-CD3 in Nonalcoholic steatohepatitis (NASH), sponsored by Hadassah Medical Organization. Started Sep 2010; status: completed.
02
Drugs
muromonab-CD3
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT01205087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01205087.